Ag-013736 (Axitinib) For The Treatment Of Metastatic Renal Cell Cancer

Trial Profile

Ag-013736 (Axitinib) For The Treatment Of Metastatic Renal Cell Cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Axitinib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms AGILE
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Mar 2018 Planned End Date changed from 1 May 2021 to 30 May 2021.
    • 12 Dec 2017 Planned End Date changed from 1 Nov 2017 to 1 May 2021.
    • 30 Mar 2017 Results of retrospective data analysis two studies including this study published in the Targeted Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top